TruDiagnostic Receives NIH Grant to Enhance Epigenetic Diagnostic Innovations
On October 7, 2025, TruDiagnostic, a pioneering company in epigenetic testing and health analytics based in Lexington, Kentucky, proudly announced that it has been awarded a competitive grant through the Small Business Innovation Research (SBIR) program from the National Institutes of Health (NIH). This significant funding is aimed at supporting the development of the company's cutting-edge W-Function Epigenomic Roadmap, a next-generation model designed to provide insights into how DNA methylation evolves over time, ultimately aiding in the prediction and prevention of chronic diseases.
Most existing diagnostic tools predominantly rely on static or occasional data samples that often fail to capture the complex nature of biological evolution. In contrast, the W-Function model adopts a systems-based methodology, mapping the dynamic shifts in DNA methylation. This innovative approach offers fresh perspectives into disease onset, progression, and treatment responses.
Leveraging the world’s largest longitudinal dataset on methylation, TruDiagnostic seeks to pinpoint causal epigenetic changes while minimizing random noise that has historically hindered accurate predictions. The implications of this research are far-reaching: enhanced health forecasts, timely intervention opportunities, and the discovery of new therapeutic targets for drug development.
TruDiagnostic’s robust platform facilitates this research endeavor, boasting a vast repository of data from thousands of patients who have undergone your testing and re-testing processes across its network of professional providers and researchers.
The initial focus of this research will include cardiovascular diseases, type 2 diabetes, and mortality risk assessment, with plans to eventually extend applications across various chronic conditions. Once the W-Function Epigenomic Roadmap has been validated, it holds the potential to:
Ryan Smith, the founder and director of research at TruDiagnostic, shared insights about this milestone: “This award underscores the significance of our mission to push the frontiers of precision health. The W-Function Epigenomic Roadmap has the potential to revolutionize our understanding of disease risk, transitioning from a reactive model of healthcare to proactive, personalized health strategies.”
TruDiagnostic stands out as a premier health data firm and CLIA-certified laboratory specializing in epigenetic testing and research. Housing the largest private DNA methylation database globally, TruDiagnostic collaborates with esteemed biotech developers, researchers, and academic institutions to translate the healthcare potential of epigenetic data into practical applications. Their TruAge biological aging tests provide in-depth insights, empowering individuals and healthcare professionals to make informed decisions regarding lifestyle and medical interventions, all based on the evolving patterns found in the epigenome.
For additional information about TruDiagnostic, please visit www.trudiagnostic.com. For media inquiries, reach out at [email protected]
A New Framework for Dynamic Health Measurement
Most existing diagnostic tools predominantly rely on static or occasional data samples that often fail to capture the complex nature of biological evolution. In contrast, the W-Function model adopts a systems-based methodology, mapping the dynamic shifts in DNA methylation. This innovative approach offers fresh perspectives into disease onset, progression, and treatment responses.
Leveraging the world’s largest longitudinal dataset on methylation, TruDiagnostic seeks to pinpoint causal epigenetic changes while minimizing random noise that has historically hindered accurate predictions. The implications of this research are far-reaching: enhanced health forecasts, timely intervention opportunities, and the discovery of new therapeutic targets for drug development.
TruDiagnostic’s robust platform facilitates this research endeavor, boasting a vast repository of data from thousands of patients who have undergone your testing and re-testing processes across its network of professional providers and researchers.
Transformative Potential Across Medicine
The initial focus of this research will include cardiovascular diseases, type 2 diabetes, and mortality risk assessment, with plans to eventually extend applications across various chronic conditions. Once the W-Function Epigenomic Roadmap has been validated, it holds the potential to:
- - Improve early detection of chronic diseases,
- - Tailor personalized treatment strategies through real-time health monitoring,
- - Accelerate the drug discovery process by utilizing actionable epigenetic markers.
Ryan Smith, the founder and director of research at TruDiagnostic, shared insights about this milestone: “This award underscores the significance of our mission to push the frontiers of precision health. The W-Function Epigenomic Roadmap has the potential to revolutionize our understanding of disease risk, transitioning from a reactive model of healthcare to proactive, personalized health strategies.”
About TruDiagnostic
TruDiagnostic stands out as a premier health data firm and CLIA-certified laboratory specializing in epigenetic testing and research. Housing the largest private DNA methylation database globally, TruDiagnostic collaborates with esteemed biotech developers, researchers, and academic institutions to translate the healthcare potential of epigenetic data into practical applications. Their TruAge biological aging tests provide in-depth insights, empowering individuals and healthcare professionals to make informed decisions regarding lifestyle and medical interventions, all based on the evolving patterns found in the epigenome.
For additional information about TruDiagnostic, please visit www.trudiagnostic.com. For media inquiries, reach out at [email protected]
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.